-+ 0.00%
-+ 0.00%
-+ 0.00%

Cansino announced that the company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the adsorbed acell-free pertussis vaccine was approved to conduct clinical trials in people aged 4 to 5 to prevent pertussis, diphtheria, and tetanus. The version of the vaccine for people aged 6 and above has been included in the priority review and approval process, and the marketing license application has been accepted. Approved this time, it is proposed to expand the age of booster vaccination for this vaccine to 4 to 6 years to fill the gap in pre-school immunization. Currently, the vaccine is still in need of clinical trials, and there is uncertainty about the progress of subsequent marketing.

Zhitongcaijing·11/16/2026 09:57:08
Listen to the news
Cansino announced that the company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the adsorbed acell-free pertussis vaccine was approved to conduct clinical trials in people aged 4 to 5 to prevent pertussis, diphtheria, and tetanus. The version of the vaccine for people aged 6 and above has been included in the priority review and approval process, and the marketing license application has been accepted. Approved this time, it is proposed to expand the age of booster vaccination for this vaccine to 4 to 6 years to fill the gap in pre-school immunization. Currently, the vaccine is still in need of clinical trials, and there is uncertainty about the progress of subsequent marketing.